What is the difference between Palmitoyl Tripeptide-1 and GHK-Cu?

Both contain the GHK tripeptide sequence. GHK-Cu combines GHK with a copper ion and is used both topically and as a research injectable. Palmitoyl Tripeptide-1 conjugates GHK with palmitic acid for optimised topical penetration. GHK-Cu has broader research applications, while Palmitoyl Tripeptide-1 is specifically designed for cosmetic anti-ageing.

What is Matrixyl 3000?

Matrixyl 3000 is a branded combination of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7, developed by Sederma. The combination provides both collagen-stimulating (matrikine) and anti-inflammatory effects, offering a comprehensive anti-ageing approach in a single peptide complex.

How long does it take to see results?

Clinical studies typically show measurable improvements after 2-4 months of consistent twice-daily application. Some users report improvements in skin texture and hydration within 4-6 weeks, while wrinkle depth reduction requires longer consistent use.

Can Palmitoyl Tripeptide-1 replace Botox?

No. Palmitoyl Tripeptide-1 stimulates collagen production for gradual skin improvement, while Botox (botulinum toxin) temporarily paralyses muscles to prevent expression lines. They work through completely different mechanisms and produce different types of results. Some people use both as complementary approaches.

Is this peptide safe for sensitive skin?

Palmitoyl Tripeptide-1 is generally very well tolerated, even by sensitive skin types. It is non-irritating in standard dermatological testing. However, individual sensitivities can occur with any cosmetic ingredient. Patch testing is recommended for very sensitive skin.

Can I use this with retinol?

Yes, Palmitoyl Tripeptide-1 is compatible with retinol and retinoids. The combination may be complementary—retinol increases cell turnover while the peptide stimulates collagen production. Introduce gradually to avoid irritation, particularly when starting retinol.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 22 February 2026

Share:X Post LinkedIn

Cosmetic Peptides•Updated 2026-02-22•4 min read

What Is Palmitoyl Tripeptide-1? Benefits, Research & Safety

A lipopeptide signal peptide that mimics collagen breakdown fragments to stimulate new collagen and elastin production for anti-ageing skincare.

Share:X Post LinkedIn

Also known as:

Pal-GHK

Palmitoyl Oligopeptide

Biopeptide CL

CLimited human evidenceUK: Licensed medicine (UK)WADA: Low sport risk

UK summary: Cosmetic peptide (lipopeptide form of GHK) regulated under UK cosmetics legislation. Component of the Matrixyl 3000 complex. Topical only.

Quick Facts

Overview

Palmitoyl Tripeptide-1 (Pal-GHK) is a synthetic lipopeptide consisting of the tripeptide glycine-histidine-lysine (GHK) conjugated with palmitic acid for enhanced skin penetration. It belongs to the matrikine class of cosmetic peptides—signal peptides that mimic the fragments produced during collagen breakdown to stimulate new collagen synthesis. The GHK sequence is the same found in the copper peptide GHK-Cu, but in Palmitoyl Tripeptide-1, the palmitic acid conjugation replaces the copper ion, optimising the molecule for topical skincare delivery. This lipopeptide approach enhances penetration through the skin's lipid barrier while maintaining the signalling properties of the GHK sequence. Palmitoyl Tripeptide-1 is widely used in professional anti-ageing skincare formulations, often in combination with Palmitoyl Tetrapeptide-7 (the combination marketed as Matrixyl 3000). It represents one of the most commercially successful cosmetic peptides with extensive in vitro and clinical evidence for anti-ageing effects. This peptide is a cosmetic ingredient, not a pharmaceutical. It is used in topical skincare products and does not require prescription.

Evidence standards summary

Palmitoyl Tripeptide-1 — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

CLimited human evidenceOverall grade against our evidence grading methodology.

Cosmetic peptide (lipopeptide form of GHK) regulated under UK cosmetics legislation. Component of the Matrixyl 3000 complex. Topical only.

02Human evidence grade

CLimited human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

BModerate human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Regulated as a cosmetic ingredient. Widely available in skincare products without prescription.
EU: Listed in the EU cosmetic ingredient database (CosIng). Permitted in cosmetic formulations.
Notes: Classified as a cosmetic ingredient globally. Not a pharmaceutical or research peptide. Widely used in commercial anti-ageing products.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Equivalent to medical anti-ageing treatments.
Injectable use is safe.

07Common internet claims

Marketed in finished cosmetic skincare; component of the Matrixyl 3000 complex.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Stimulates collagen synthesis topically”	C	Yes	Low	Manufacturer-led human trials of formulations containing Palmitoyl Tripeptide-1 show measurable skin-elasticity improvements.

09Safety uncertainty score

Low — well characterised

Safety profile is well-characterised in published human data.

10Known adverse signals

Generally well-tolerated topically.
Rare skin sensitivity.

11Drug-interaction uncertainty

Low

Drug-interaction picture documented in the prescribing information.

12Anti-doping status

WADA: Low sport riskWADA strict-liability framing applies.

13UK legal position

UK: Licensed medicine (UK)

Regulated as a cosmetic ingredient. Widely available in skincare products without prescription.

14EU legal position

Listed in the EU cosmetic ingredient database (CosIng). Permitted in cosmetic formulations.

15What this page cannot tell you

Whether a particular finished product contains the labelled concentration.
Real-world effect magnitude vs topical retinoid.

16Last reviewed

Last reviewed: 22 February 2026

Next review due: 22 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Independent comparative-effectiveness trials limited.

19Safer alternatives / established care pathways

Sunscreen + topical retinoid as foundation skincare.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is this an appropriate addition to my skincare routine?

Discovery & History

Palmitoyl Tripeptide-1 was developed through cosmetic peptide research in the early 2000s, building on the understanding that collagen degradation fragments (matrikines) serve as signals to stimulate new collagen production. The GHK sequence had been identified as a key signalling tripeptide in wound healing and tissue remodelling research. Sederma, a French cosmetic ingredients company, developed the palmitoylated version to improve topical bioavailability. The palmitic acid conjugation was a key innovation, enabling the hydrophilic peptide to penetrate the skin's lipid-rich stratum corneum. The combination with Palmitoyl Tetrapeptide-7 was marketed as Matrixyl 3000, becoming one of the most widely adopted peptide complexes in cosmetic anti-ageing formulations globally. Clinical studies demonstrated visible improvements in wrinkle depth and skin firmness.

Mechanism of Action

Palmitoyl Tripeptide-1 works through matrikine signalling: **Matrikine Signalling** The GHK sequence mimics the fragments produced when collagen is broken down by matrix metalloproteinases (MMPs). These fragments serve as "alarm signals" that trigger fibroblasts to produce new collagen, effectively turning the natural degradation signal into a regenerative stimulus. **Collagen Stimulation** Activates fibroblasts to increase production of Type I collagen—the primary structural protein responsible for skin firmness and resistance to wrinkling. **Elastin Support** In addition to collagen, Palmitoyl Tripeptide-1 may stimulate elastin production, supporting skin elasticity and resilience. **Glycosaminoglycan Production** Research suggests the peptide promotes production of glycosaminoglycans (including hyaluronic acid) in the dermal extracellular matrix, supporting skin hydration and volume. **Enhanced Penetration** The palmitic acid conjugation enables the peptide to cross the stratum corneum lipid barrier, reaching the dermis where fibroblasts reside. This is critical for a topical peptide to exert biological effects.

Researched Benefits

Based on preclinical and clinical research findings:

1
Stimulation of Type I collagen synthesis in fibroblasts
2
Visible reduction in wrinkle depth in clinical studies
3
Improvement in skin firmness and elasticity
4
Enhanced extracellular matrix production
5
Synergistic effects when combined with Palmitoyl Tetrapeptide-7 (Matrixyl 3000)
6
Good skin tolerability with minimal irritation potential

Claim vs Evidence

How popular claims about Palmitoyl Tripeptide-1 stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Stimulates collagen synthesis topically”	C	Yes	Low	Manufacturer-led human trials of formulations containing Palmitoyl Tripeptide-1 show measurable skin-elasticity improvements.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Typical concentration in skincare: 2-5% of the peptide complex (Matrixyl 3000)
Frequency	Twice daily application (morning and evening)
Duration	Clinical studies typically 2-4 months; ongoing use for maintained benefits
Notes	Applied topically as part of serum or moisturiser formulations. Best results with consistent, long-term use. Often combined with Palmitoyl Tetrapeptide-7 and other active ingredients.

Administration Routes

Routes studied in research settings (educational only):

Topical (serums, creams, moisturisers)

Half-Life	Stability
Topical application; systemic pharmacokinetics not relevant. Effects depend on continuous application.	Stable in properly formulated cosmetic products. Protected from excessive heat and light.

Safety Profile & Known Risks

Commonly Reported Side Effects

Very well tolerated
Rare mild skin irritation in sensitive individuals

Rare Risks & Concerns

Allergic contact dermatitis (very rare)
Not associated with systemic side effects

Contraindications

Known hypersensitivity to the ingredient
Open wounds or broken skin (apply to intact skin only)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Regulated as a cosmetic ingredient. Widely available in skincare products without prescription.

🇪🇺 European Union

Listed in the EU cosmetic ingredient database (CosIng). Permitted in cosmetic formulations.

Classified as a cosmetic ingredient globally. Not a pharmaceutical or research peptide. Widely used in commercial anti-ageing products.

Clinical Studies Summary

Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism.

Collagen metabolism is regulated by circadian rhythms. Chronomodulated baicalin and PT-1 application synergistically optimize collagen metabolism and improve skin quality.

J Cosmet Dermatol. 2026View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

none

Approved product

Yes

BUDDATE REGES INTENSIVE TREATMENT

No registered clinical trials.

ClinicalTrials.gov holds no interventional study of Palmitoyl Tripeptide-1. Any claim about what it does in humans does not rest on a registered trial.

Adverse event reports (FDA FAERS)

No reactions reported against this product. FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Palmitoyl Tripeptide-1?

Source research-grade Palmitoyl Tripeptide-1 from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Palmitoyl Tripeptide-1